Bio News
AI drug developer Moleculargnosis increased protein expression 200-fold using AI technology and correctly identified 26 of 30 PD-L1-targeting nanobody candidates in experiments. In addition, an AI-designed TNFα-targeting nanobody achieved a strong binding affinity of 51 picomolar (pM). The company plans to use its proprietary AI platform to shift the drug development paradigm from conventional “molecule screening” to “molecule design.”
BIOBOOK TEAM
biobookmedia@biobook.co.krRoche’s New Drug for Uveitic Macular Edema Faces FDA Decision in July 2027
BMS Reports Concurrent Phase 3 Success in Idiopathic Pulmonary Fibrosis and Solid Tumors
Merck’s $1.3 trillion eye disease drug raises safety and efficacy concerns: “Limited competitiveness”
CHA Biotech Holds 24.23% Stake in CMG Pharmaceutical as Share Consolidation Reduces Its Share Count
Rural Development Administration Develops Two Molecular Markers to Identify Leaf Splitting in Squash
MFDS Begins Distribution of Internationally Certified Reference Materials, Including 24 New Items, for a Total of 882
